Development of Fluorescent Biosensors and Inhibitors to Probe and Target CDK4/Cyclin D in Melanoma Camille Prevel
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Core Lab Brochure
CHOOSE THE MOST TRUSTED LONG-READ TECHNOLOGY FOR YOUR CORE Sequence with Confidence The Sequel® II and IIe Systems are powered by Single Molecule, Real-Time (SMRT®) Sequencing, a technology proven to produce highly accurate long reads, known as HiFi reads, for sequencing data you and your customers can trust. SMRT SEQUENCING IS SMART BUSINESS HiFi Reads: PacBio is the only sequencing technology to offer highly accurate long reads. Because HiFi reads are extremely accurate, downstream analysis is simplified and streamlined, requiring less compute time than the error-prone long reads of other technologies. High Throughput: The Sequel II and IIe Systems have high data yields on robust, highly automated platforms to increase productivity and reduce project costs. Efficient and Easy-To-Use Workflows: Our end-to-end solutions feature library preparation in <3 hours and many push- button analysis workflows, so you can run projects quickly and easily. Support: All of our products are backed by a global team of scientists, bioinformaticians, and engineers who stand ready to provide you with outstanding service. OUTSTANDING PERFORMANCE AND RELIABILITY 99% of runs on the Sequel II System completed successfully Sequel II Systems provide reliable performance with the total bases produced by the PacBio fleet steadily increasing, and 99% of runs completed successfully. “In our experience, the Sequel II System was essentially production-ready right out of the box. We have used it for a range of applications and sample types — from human genome sequencing to metagenome and microbiome profiling to non-model plant and animal genomes — and results have been very good.” — Luke Tallon, Director of the Genomics Resource Center at Maryland Genomics pacb.com/Sequel SMRT SEQUENCING APPLICATIONS – EFFICIENT AND COST EFFECTIVE The Sequel II and IIe Systems support a wide range of applications, each adding unique value to a sequencing study. -
Sensors 2010, 10, 6796-6820; Doi:10.3390/S100706796 OPEN ACCESS Sensors ISSN 1424-8220
Sensors 2010, 10, 6796-6820; doi:10.3390/s100706796 OPEN ACCESS sensors ISSN 1424-8220 www.mdpi.com/journal/sensors Review Intelligent Chiral Sensing Based on Supramolecular and Interfacial Concepts Katsuhiko Ariga 1,2,*, Gary J. Richards 1, Shinsuke Ishihara 1, Hironori Izawa 1,2 and Jonathan P. Hill 1,2 1 World Premier International (WPI) Research Center for Materials Nanoarchitectonics (MANA), National Institute for Materials Science (NIMS), 1-1 Namiki, Tsukuba 305-0044, Japan 2 Japan Science and Technology Agency, CREST, 1-1 Namiki, Tsukuba 305-0044, Japan * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +81-29-860-4597; Fax: +81-29-860-4832. Received: 17 June 2010; in revised form: 7 July 2010 / Accepted: 8 July 2010 / Published: 13 July 2010 Abstract: Of the known intelligently-operating systems, the majority can undoubtedly be classed as being of biological origin. One of the notable differences between biological and artificial systems is the important fact that biological materials consist mostly of chiral molecules. While most biochemical processes routinely discriminate chiral molecules, differentiation between chiral molecules in artificial systems is currently one of the challenging subjects in the field of molecular recognition. Therefore, one of the important challenges for intelligent man-made sensors is to prepare a sensing system that can discriminate chiral molecules. Because intermolecular interactions and detection at surfaces are respectively parts of supramolecular chemistry -
Biosensor Laboratory Selected Publications 1. Irina Sorokulova
Biosensor Laboratory Selected Publications 1. Irina Sorokulova, Eric Olsen, Vitaly Vodyanoy, Bacteriophage biosensors for antibiotic resistant bacteria. Expert Rev Med Devices. 2014 Mar;11(2):175-86. doi: 10.1586/17434440.2014.882767. 2. I.Sorokulova, R. Guntupalli, E. Olsen, L. Globa, O. Pustovyy, V. Vodyanoy. Lytic Phage in Biosensing, ECS Transactions, 58 (23) 1-7 (2014) 10.1149/05823.000lecst ©The Electrochemical Society. 3. Jia, H, Pustovyy, OM, Waggoner, P, Beyers, RJ, Schumacher, J, Wildey, C, Barrett, J, Morrison, E, Salibi, N, Denney, TS, Vodyanoy, VJ, Deshpande, G. Functional MRI of the olfactory system in conscious dogs. PLoS One, 9:e86362 (2014). 4. Kyathanahally SP, Jia H, Pustovyy OM, Waggoner P, Beyers R, Schumacher J, Barrett J, Morrison EE, Salibi N, Denney TS, Vodyanoy VJ, Deshpande G. 2014. Anterior- posterior dissociation of the default mode network in dogs. Brain structure & function: 1- 14. 5. Moore T, Globa L, Barbaree J., Vodyanoy V., Sorokulova I. Antagonistic Activity of Bacillus Bacteria against Food-Borne Pathogens. Journal of Probiotics and Health. Vol. 1(3): 1-6 (2013) 6. Vitaly J. Vodyanoy, Yuri Mnyukh, The Physical Nature of "Giant" Magnetocaloric and Electrocaloric Effects, American Journal of Materials Science, Vol. 3 No. 5, 2013, pp. 105-109. doi: 10.5923/j.materials.20130305.01. 7. Moore T, Sorokulova I, Pustovyy O, Globa L, Vodyanoy V (2013). Microscopic evaluation of vesicles shed by rat erythrocytes at elevated temperatures. Journal of Thermal Biology, 38:487-492. 8. Moore T, Sorokulova I, Pustovyy O, Globa L, Pascoe D, Rudisill M, Vodyanoy V. (2013) Microscopic evaluation of vesicles shed by erythrocytes at elevated temperatures. -
Detection of Driver Mutations in FFPE Samples from Patients with Verified Malignant Melanoma
Neoplasma 2019; 66(1): 33–38 33 doi:10.4149/neo_2018_180115N31 Detection of driver mutations in FFPE samples from patients with verified malignant melanoma B. MALICHEROVA1,2,#,*, T. BURJANIVOVA1,2,#, E. MINARIKOVA3, I. KASUBOVA1,2, T. PECOVA3, M. BOBROVSKA4, I. HOMOLA5, Z. LASABOVA1,2,6, L. PLANK1,2,4 1Biomedical Center Martin, Jessenius Faculty of Medicine in Martin, Commenius University in Bratislava (JFM CU), Slovakia; 2Division of Oncology JFM CU, Martin, Slovakia; 3Clinic of Dermatovenerology, Jessenius Faculty of Medicine and University Hospital in Martin, Martin, Slovakia; 4Department of Pathological Anatomy, Jessenius Faculty of Medicine and University Hospital in Martin, Martin, Slovakia; 5Depart- ment of Plastic Surgery, Jessenius Faculty of Medicine and University Hospital in Martin, Martin, Slovakia; 6Department of Molecular Biology, JFM CU, Martin Slovakia *Correspondence: [email protected] #Contributed equally to this work. Received January 15, 2018 / Accepted April 24, 2018 Malignant melanoma is an oncological disease characterized by etiologic heterogeneity and it has increasing incidence and mortality in the Slovak Republic. While it is treated surgically in combination with chemotherapy, targeted therapy, and immunotherapy, malignant melanomas can ulcerate and are susceptible to infections. These are highly aggressive cancers with metastasis, and recent studies have shown the presence of mutations in RAC1, PPP6C and STK19 genes in melanoma patients. Mutations in these genes are driver mutations; important in oncogenesis and providing selective advantage to tumor cells. The aim of our study is to establish a method to detect driver mutations in formalin-fixed, paraffin embedded (FFPE) tissue DNA. We applied Sanger sequencing to detect driver somatic mutations in RAC1, PPP6C, STK19 and BRAF genes in patients with malignant melanoma. -
Investigating the Role of Cdk11in Animal Cytokinesis
Investigating the Role of CDK11 in Animal Cytokinesis by Thomas Clifford Panagiotou A thesis submitted in conformity with the requirements for the degree of Master of Science Department of Molecular Genetics University of Toronto © Copyright by Thomas Clifford Panagiotou (2020) Investigating the Role of CDK11 in Animal Cytokinesis Thomas Clifford Panagiotou Master of Science Department of Molecular Genetics University of Toronto 2020 Abstract Finely tuned spatio-temporal regulation of cell division is required for genome stability. Cytokinesis constitutes the final stages of cell division, from chromosome segregation to the physical separation of cells, abscission. Abscission is tightly regulated to ensure it occurs after earlier cytokinetic events, like the maturation of the stem body, the regulatory platform for abscission. Active Aurora B kinase enforces the abscission checkpoint, which blocks abscission until chromosomes have been cleared from the cytokinetic machinery. Currently, it is unclear how this checkpoint is overcome. Here, I demonstrate that the cyclin-dependent kinase CDK11 is required for cytokinesis. Both inhibition and depletion of CDK11 block abscission. Furthermore, the mitosis-specific CDK11p58 kinase localizes to the stem body, where its kinase activity rescues the defects of CDK11 depletion and inhibition. These results suggest a model whereby CDK11p58 antagonizes Aurora B kinase to overcome the abscission checkpoint to allow for successful completion of cytokinesis. ii Acknowledgments I am very grateful for the support of my family and friends throughout my studies. I would also like to express my deep gratitude to Wilde Lab members, both past and present, for their advice and collaboration. In particular, I am very grateful to Matthew Renshaw, whose work comprises part of this thesis. -
Next-Generation Sequencing
Tinhofer et al. Radiation Oncology (2015) 10:183 DOI 10.1186/s13014-015-0481-x REVIEW Open Access Next-generation sequencing: hype and hope for development of personalized radiation therapy? Ingeborg Tinhofer1,2*, Franziska Niehr1,2, Robert Konschak1,2, Sandra Liebs2, Matthias Munz3, Albrecht Stenzinger4, Wilko Weichert4,5, Ulrich Keilholz6 and Volker Budach1,2 Abstract The introduction of next-generation sequencing (NGS) in the field of cancer research has boosted worldwide efforts of genome-wide personalized oncology aiming at identifying predictive biomarkers and novel actionable targets. Despite considerable progress in understanding the molecular biology of distinct cancer entities by the use of this revolutionary technology and despite contemporaneous innovations in drug development, translation of NGS findings into improved concepts for cancer treatment remains a challenge. The aim of this article is to describe shortly the NGS platforms for DNA sequencing and in more detail key achievements and unresolved hurdles. A special focus will be given on potential clinical applications of this innovative technique in the field of radiation oncology. Introduction and Wong et al. [11]. We will instead focus on key achieve- Recent technological advances in DNA sequencing with ments in cancer genetics and potential clinical applications of greater speed and resolution at lower costs has provided this innovative technique in the field of radiation oncology. new insights in cancer genetics. The next-generation se- quencing (NGS) technology is tremendously facilitating the in-depth genome-wide search for genetic alterations The advantages of NGS which might significantly contribute to aggressive and/or Next-generation sequencing has rapidly been evolv- treatment-resistant phenotypes of cancers, thereby es- ing within the last decade [10]. -
A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated. -
Support Info
Electronic Supplementary Material (ESI) for RSC Advances. This journal is © The Royal Society of Chemistry 2014 Supporting Information Design and synthesis of pyrrole–5-(2,6-dichlorobenzyl)sulfonylindolin-2-ones with C- 3’ side chains as potent Met kinase inhibitors Chia-Wei Liu,a Chun-Liang Lai,a Yu-Hsiang Lin,a Li-Wei Teng,a Sheng-chuan Yang,a Win-Yin Wei,a Shu Fu Lin,a Ju-Ying Yang,a Hung-Jyun Huang,a Ru-Wen Wang,a Chao-Cheng Chiang,a Mei-Hui Lee,a Yu- Chuan Wang,b Shih-Hsien Chuang,a Jia-Ming Chang,a Ying-Shuan E. Lee,a and Jiann-Jyh Huang*a,b aDevelopment Center for Biotechnology, No. 101, Lane 169, Kangning St., Xizhi District, New Taipei City 22180, Taiwan bDepartment of Applied Chemistry, National Chiayi University, No. 300, Syuefu Rd., Chiayi City 60004, Taiwan *Corresponding Author. Tel.: +886 5 271 7959; Fax: +886 5 271 7901. E-mail address: [email protected] (J.-J. Huang) Table of Contents: Page Supporting Figure. Ligplot diagrams of the ATP binding site of Met S2 complexed with compounds 2 and 20. Supporting Table. Kinase profiling data of compound 20. S3 References S10 - S1 - Supporting Figure. Ligplot diagrams1 of the ATP binding site of Met complexed with compounds 2 and 20: (A) Met with 2, and (B) Met with 20. - S2 - Supporting Table. Kinase profiling data of 20. Ambit KinomeScan Kinase Profiling (1.0 μM test concentration): Percentage of Percentage of Ambit Gene Symbol control (%) Ambit Gene Symbol control (%) 20 20 AAK1 68 ARK5 27 ABL1(E255K)-phosphorylated 85 ASK1 100 ABL1(F317I)-nonphosphorylated 78 ASK2 67 -
Profiling Data
Compound Name DiscoveRx Gene Symbol Entrez Gene Percent Compound Symbol Control Concentration (nM) JNK-IN-8 AAK1 AAK1 69 1000 JNK-IN-8 ABL1(E255K)-phosphorylated ABL1 100 1000 JNK-IN-8 ABL1(F317I)-nonphosphorylated ABL1 87 1000 JNK-IN-8 ABL1(F317I)-phosphorylated ABL1 100 1000 JNK-IN-8 ABL1(F317L)-nonphosphorylated ABL1 65 1000 JNK-IN-8 ABL1(F317L)-phosphorylated ABL1 61 1000 JNK-IN-8 ABL1(H396P)-nonphosphorylated ABL1 42 1000 JNK-IN-8 ABL1(H396P)-phosphorylated ABL1 60 1000 JNK-IN-8 ABL1(M351T)-phosphorylated ABL1 81 1000 JNK-IN-8 ABL1(Q252H)-nonphosphorylated ABL1 100 1000 JNK-IN-8 ABL1(Q252H)-phosphorylated ABL1 56 1000 JNK-IN-8 ABL1(T315I)-nonphosphorylated ABL1 100 1000 JNK-IN-8 ABL1(T315I)-phosphorylated ABL1 92 1000 JNK-IN-8 ABL1(Y253F)-phosphorylated ABL1 71 1000 JNK-IN-8 ABL1-nonphosphorylated ABL1 97 1000 JNK-IN-8 ABL1-phosphorylated ABL1 100 1000 JNK-IN-8 ABL2 ABL2 97 1000 JNK-IN-8 ACVR1 ACVR1 100 1000 JNK-IN-8 ACVR1B ACVR1B 88 1000 JNK-IN-8 ACVR2A ACVR2A 100 1000 JNK-IN-8 ACVR2B ACVR2B 100 1000 JNK-IN-8 ACVRL1 ACVRL1 96 1000 JNK-IN-8 ADCK3 CABC1 100 1000 JNK-IN-8 ADCK4 ADCK4 93 1000 JNK-IN-8 AKT1 AKT1 100 1000 JNK-IN-8 AKT2 AKT2 100 1000 JNK-IN-8 AKT3 AKT3 100 1000 JNK-IN-8 ALK ALK 85 1000 JNK-IN-8 AMPK-alpha1 PRKAA1 100 1000 JNK-IN-8 AMPK-alpha2 PRKAA2 84 1000 JNK-IN-8 ANKK1 ANKK1 75 1000 JNK-IN-8 ARK5 NUAK1 100 1000 JNK-IN-8 ASK1 MAP3K5 100 1000 JNK-IN-8 ASK2 MAP3K6 93 1000 JNK-IN-8 AURKA AURKA 100 1000 JNK-IN-8 AURKA AURKA 84 1000 JNK-IN-8 AURKB AURKB 83 1000 JNK-IN-8 AURKB AURKB 96 1000 JNK-IN-8 AURKC AURKC 95 1000 JNK-IN-8 -
Genome-Wide DNA Methylation Analysis of KRAS Mutant Cell Lines Ben Yi Tew1,5, Joel K
www.nature.com/scientificreports OPEN Genome-wide DNA methylation analysis of KRAS mutant cell lines Ben Yi Tew1,5, Joel K. Durand2,5, Kirsten L. Bryant2, Tikvah K. Hayes2, Sen Peng3, Nhan L. Tran4, Gerald C. Gooden1, David N. Buckley1, Channing J. Der2, Albert S. Baldwin2 ✉ & Bodour Salhia1 ✉ Oncogenic RAS mutations are associated with DNA methylation changes that alter gene expression to drive cancer. Recent studies suggest that DNA methylation changes may be stochastic in nature, while other groups propose distinct signaling pathways responsible for aberrant methylation. Better understanding of DNA methylation events associated with oncogenic KRAS expression could enhance therapeutic approaches. Here we analyzed the basal CpG methylation of 11 KRAS-mutant and dependent pancreatic cancer cell lines and observed strikingly similar methylation patterns. KRAS knockdown resulted in unique methylation changes with limited overlap between each cell line. In KRAS-mutant Pa16C pancreatic cancer cells, while KRAS knockdown resulted in over 8,000 diferentially methylated (DM) CpGs, treatment with the ERK1/2-selective inhibitor SCH772984 showed less than 40 DM CpGs, suggesting that ERK is not a broadly active driver of KRAS-associated DNA methylation. KRAS G12V overexpression in an isogenic lung model reveals >50,600 DM CpGs compared to non-transformed controls. In lung and pancreatic cells, gene ontology analyses of DM promoters show an enrichment for genes involved in diferentiation and development. Taken all together, KRAS-mediated DNA methylation are stochastic and independent of canonical downstream efector signaling. These epigenetically altered genes associated with KRAS expression could represent potential therapeutic targets in KRAS-driven cancer. Activating KRAS mutations can be found in nearly 25 percent of all cancers1. -
Genome-Wide Sirna Screen for Modulators of Cell Death Induced by Proteasome Inhibitor Bortezomib
Published OnlineFirst May 11, 2010; DOI: 10.1158/0008-5472.CAN-09-4428 Published OnlineFirst on May 11, 2010 as 10.1158/0008-5472.CAN-09-4428 Integrated Systems and Technologies Cancer Research Genome-Wide siRNA Screen for Modulators of Cell Death Induced by Proteasome Inhibitor Bortezomib Siquan Chen1, Jonathan L. Blank2, Theodore Peters1, Xiaozhen J. Liu2, David M. Rappoli1, Michael D. Pickard3, Saurabh Menon1, Jie Yu2, Denise L. Driscoll2, Trupti Lingaraj2, Anne L. Burkhardt2, Wei Chen2, Khristofer Garcia1, Darshan S. Sappal2, Jesse Gray1, Paul Hales1, Patrick J. Leroy2, John Ringeling1, Claudia Rabino2, James J. Spelman2, Jay P. Morgenstern1, and Eric S. Lightcap2 Abstract Multiple pathways have been proposed to explain how proteasome inhibition induces cell death, but me- chanisms remain unclear. To approach this issue, we performed a genome-wide siRNA screen to evaluate the genetic determinants that confer sensitivity to bortezomib (Velcade (R); PS-341). This screen identified 100 genes whose knockdown affected lethality to bortezomib and to a structurally diverse set of other proteasome inhibitors. A comparison of three cell lines revealed that 39 of 100 genes were commonly linked to cell death. We causally linked bortezomib-induced cell death to the accumulation of ASF1B, Myc, ODC1, Noxa, BNIP3, Gadd45α, p-SMC1A, SREBF1, and p53. Our results suggest that proteasome inhibition promotes cell death primarily by dysregulating Myc and polyamines, interfering with protein translation, and disrupting essential DNA damage repair pathways, leading to programmed cell death. Cancer Res; 70(11); OF1–9. ©2010 AACR. Introduction active oxygen species (ROS), stabilization of Myc and Noxa, and induction of endoplasmic reticulum (ER) stress, any of The primary targets of most cancer chemotherapies are which may trigger cell death (1–4). -
Strategies and Opportunities for Small Molecule Drug Discovery to Target Neurodegenerative Diseases Andrea I
bioRxiv preprint doi: https://doi.org/10.1101/2020.04.01.020206; this version posted April 2, 2020. The copyright holder has placed this preprint (which was not certified by peer review) in the Public Domain. It is no longer restricted by copyright. Anyone can legally share, reuse, remix, or adapt this material for any purpose without crediting the original authors. Defining the Neural Kinome: Strategies and Opportunities for Small Molecule Drug Discovery to Target Neurodegenerative Diseases Andrea I. Krahn, Carrow Wells, David H. Drewry, Lenore K. Beitel, Thomas M. Durcan, Alison D. Axtman* ABSTRACT: Kinases are highly tractable drug targets that have reached unparalleled success in fields such as cancer but whose potential has not yet been realized in neuroscience. There are currently 55 approved small molecule kinase-targeting drugs, 48 of which have an anti-cancer indication. The intrinsic complexity linked to central nervous system (CNS) drug development and a lack of validated targets has hindered progress in developing kinase inhibitors for CNS disorders when compared to other therapeutic areas such as oncology. Identification and/or characterization of new kinases as potential drug targets for neurodegenerative diseases will create opportunities for development of CNS drugs in the future. The track record of kinase inhibitors in other disease indications supports the idea that with the best targets identified small molecule kinase modulators will become impactful therapeutics for neurodegenerative diseases. KEYWORDS: kinase, neurodegeneration,